ANG Lifesciences India Ltd
Incorporated in 2006, ANG Lifesciences India Ltd manufactures and markets finished pharmaceutical formulations in a dosage form of sterile dry powder injection vials[1]
- Market Cap ₹ 74.7 Cr.
- Current Price ₹ 57.2
- High / Low ₹ 87.0 / 44.5
- Stock P/E
- Book Value ₹ 65.3
- Dividend Yield 0.00 %
- ROCE 8.51 %
- ROE -0.46 %
- Face Value ₹ 10.0
Pros
- Stock is trading at 0.87 times its book value
- Company has a good return on equity (ROE) track record: 3 Years ROE 25.2%
- Company's median sales growth is 21.9% of last 10 years
Cons
- Company has low interest coverage ratio.
- Promoters have pledged 44.9% of their holding.
- Earnings include an other income of Rs.9.78 Cr.
- Company's cost of borrowing seems high
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
7 | 16 | 34 | 37 | 55 | 67 | 75 | 121 | 126 | 154 | 349 | 207 | 129 | |
7 | 14 | 30 | 34 | 50 | 60 | 68 | 110 | 114 | 139 | 283 | 195 | 136 | |
Operating Profit | 0 | 3 | 5 | 3 | 5 | 6 | 7 | 12 | 12 | 15 | 66 | 12 | -6 |
OPM % | 4% | 16% | 14% | 8% | 9% | 10% | 10% | 10% | 10% | 10% | 19% | 6% | -5% |
0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 10 | 10 | |
Interest | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 3 | 4 | 8 | 11 | 7 |
Depreciation | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 5 | 9 | 9 |
Profit before tax | -2 | 0 | 0 | 1 | 2 | 4 | 5 | 8 | 8 | 10 | 53 | 2 | -12 |
Tax % | 14% | 140% | 56% | 32% | 25% | 26% | 25% | 30% | 28% | 26% | 25% | 132% | |
-2 | -0 | 0 | 0 | 2 | 3 | 4 | 6 | 6 | 7 | 40 | -1 | -10 | |
EPS in Rs | -1.86 | -0.07 | 0.21 | 0.43 | 1.79 | 3.07 | 2.86 | 4.35 | 4.69 | 5.58 | 30.55 | -0.51 | -7.71 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 3% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | 29% |
5 Years: | 22% |
3 Years: | 18% |
TTM: | -52% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | -204% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | 20% |
3 Years: | 10% |
1 Year: | -32% |
Return on Equity | |
---|---|
10 Years: | 25% |
5 Years: | 24% |
3 Years: | 25% |
Last Year: | 0% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 4 | 4 | 4 | 4 | 4 | 4 | 5 | 5 | 5 | 5 | 10 | 13 | 13 |
Reserves | -1 | -1 | -1 | -1 | 1 | 4 | 18 | 24 | 29 | 36 | 73 | 72 | 72 |
3 | 13 | 11 | 10 | 12 | 14 | 17 | 22 | 21 | 42 | 61 | 56 | 58 | |
13 | 6 | 11 | 13 | 19 | 25 | 28 | 30 | 39 | 58 | 124 | 111 | 100 | |
Total Liabilities | 18 | 21 | 25 | 26 | 35 | 47 | 68 | 81 | 94 | 142 | 269 | 252 | 243 |
12 | 11 | 9 | 9 | 9 | 9 | 9 | 21 | 21 | 22 | 82 | 79 | 77 | |
CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 12 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 4 | 4 |
7 | 10 | 16 | 17 | 26 | 38 | 47 | 60 | 73 | 120 | 183 | 170 | 163 | |
Total Assets | 18 | 21 | 25 | 26 | 35 | 47 | 68 | 81 | 94 | 142 | 269 | 252 | 243 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
8 | -8 | 4 | 3 | 2 | 3 | 1 | 7 | 5 | -11 | 27 | 26 | |
-2 | -2 | -2 | -2 | -3 | -3 | -13 | -1 | -2 | -8 | -42 | -9 | |
-5 | 10 | -1 | -1 | 2 | -0 | 13 | -4 | -4 | 19 | 15 | -17 | |
Net Cash Flow | -0 | 0 | 0 | -0 | 1 | -0 | 1 | 3 | -1 | -0 | 0 | -0 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 125 | 96 | 80 | 62 | 109 | 139 | 156 | 126 | 133 | 139 | 104 | 138 |
Inventory Days | 207 | 137 | 84 | 84 | 47 | 45 | 53 | 27 | 41 | 68 | 46 | 93 |
Days Payable | 141 | 169 | 129 | 130 | 133 | 163 | 154 | 91 | 106 | 159 | 105 | 154 |
Cash Conversion Cycle | 191 | 63 | 34 | 16 | 22 | 21 | 56 | 62 | 69 | 48 | 45 | 77 |
Working Capital Days | -410 | 59 | 42 | 39 | 43 | 50 | 79 | 77 | 90 | 133 | 73 | 107 |
ROCE % | -5% | 20% | 14% | 17% | 26% | 29% | 22% | 24% | 22% | 20% | 54% | 9% |
Documents
Announcements
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
20 Apr - Certificate dated 15.04.2024 issued by Bigshare Services Pvt Ltd (RTA) for the quarter ended as at 31.03.2024
-
Compliance Certificate For The Year Ended 31.03.2024
20 Apr - Compliance certificate under Reg 7(3) ofSEBI LODR, 2015 for the year ended 31.03.2024
-
Clarification On Price Movement
10 Apr - Sir/Madam, We hereby submit the clarification about Share price movement.
-
Clarification sought from ANG Lifesciences India Ltd
9 Apr - Exchange has sought clarification from ANG Lifesciences India Ltd on April 8, 2024 with reference to significant movement in price, in order to ensure that …
- Closure of Trading Window 30 Mar
Business Overview:[1][2]
Company manufactures and sells products like injections, tablets, capsules, syrups, ointments of different varieties. It deals in 4 market segments: institutional segment, third party manufacturing, direct marketing and export market. Apart from this, company is also providing printing & packing solutions especially in mono cartons, paper printing, corrugation, aluminiumfoils (blister foils)